Today: 20 May 2026
Browse Category

NASDAQ:GILD 22 August 2025 - 20 December 2025

Gilead Sciences Stock (NASDAQ: GILD) Today: TrumpRx Drug-Pricing Deal, HIV Pipeline Momentum, and Wall Street Forecasts (Dec. 20, 2025)

Gilead Sciences Stock (NASDAQ: GILD) Today: TrumpRx Drug-Pricing Deal, HIV Pipeline Momentum, and Wall Street Forecasts (Dec. 20, 2025)

Gilead Sciences shares closed at $124.29 on Dec. 19, up 2.32%, after President Trump announced a drug pricing deal with nine major firms, including Gilead. The agreement includes Medicaid price cuts, cash-pay discounts via TrumpRx.gov, and a three-year tariff exemption tied to increased U.S. manufacturing. Gilead expects the financial impact to be manageable in 2026.
20 December 2025
··
Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

President Donald Trump and nine major drugmakers announced deals to cut U.S. drug prices for Medicaid and cash-paying patients, with discounts up to 70% off list prices and a three-year tariff reprieve. Shares of several companies rose modestly after the news. Commitments include free Eliquis for Medicaid and steep discounts on diabetes and migraine drugs. The moves reshape investor expectations for healthcare stocks heading into 2026.
20 December 2025
········
Gilead Sciences Stock (GILD) After Hours on Dec. 19, 2025: TrumpRx Pricing Deal, UK Lenacapavir Approval, and What to Watch Before the Next Market Open

Gilead Sciences Stock (GILD) After Hours on Dec. 19, 2025: TrumpRx Pricing Deal, UK Lenacapavir Approval, and What to Watch Before the Next Market Open

Gilead Sciences shares jumped 2.3% to $124.29 Friday after the company announced a three-year U.S. drug pricing deal tied to TrumpRx.gov and tariff relief, plus new U.K. approval for lenacapavir. Trading volume spiked to 24.39 million shares. After-hours, the stock edged up to $124.78. The White House said Epclusa’s U.S. price will drop from $24,920 to $2,425 under the new agreement.
20 December 2025
··
Gilead Sciences Stock (GILD) Outlook 2026: Latest News, Trodelvy Data, Dividend and Analyst Forecasts

Gilead Sciences Stock (GILD) Outlook 2026: Latest News, Trodelvy Data, Dividend and Analyst Forecasts

Gilead Sciences shares closed at $121.22 on December 5, 2025, about 6% below their 52-week high. Third-quarter revenue rose 3% year-over-year to $7.8 billion, with HIV product sales up 4% to $5.3 billion. Veklury sales dropped as COVID cases fell. The company continues to invest in oncology and cell therapy despite near-term earnings pressure.
6 December 2025
···
Gilead Sciences (GILD) Stock Outlook Before the December 1, 2025 Open: Price, News, Analyst Ratings and Forecast

Gilead Sciences (GILD) Stock Outlook Before the December 1, 2025 Open: Price, News, Analyst Ratings and Forecast

Gilead Sciences closed at $125.84 on Friday, down 1.3% and about 2.2% below its 52-week high. Trading volume was 3.1 million shares, well under the 50-day average. Truist and Mizuho issued bullish analyst notes, both setting price targets at $140, citing strong HIV drug sales and extended exclusivity for Biktarvy. Gilead shares have risen 36% over the past year.
1 December 2025
·
Gilead Stock Skyrockets on Patent Win and Game-Changing HIV Therapies

Gilead Stock Skyrockets on Patent Win and Game-Changing HIV Therapies

Gilead shares closed near $123 on Oct. 17, 2025, up 4.2% and close to 52-week highs, after extending Biktarvy’s U.S. exclusivity to 2036 and securing a CDC endorsement for Yeztugo. Q2 earnings beat forecasts, prompting raised guidance and analyst upgrades. Gilead is set to present positive Phase 3 Trodelvy data at ESMO and is expanding cell therapy with a $350M Interius BioTherapeutics deal.
18 October 2025
·
Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences Stock Soars on Patent Win and HIV Breakthroughs – Will the Rally Continue?

Gilead Sciences stock jumped over 4% on Oct. 17, 2025, closing at $122.81 and hitting a new 52-week high. The surge follows a patent settlement extending exclusivity for Biktarvy until 2036 and FDA approval of Yeztugo, a new HIV prevention shot. Gilead’s market cap stands near $150 billion after a 47% year-to-date gain. Analysts remain bullish but note concerns over U.S. drug pricing pressures.
18 October 2025
···
Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences shares rose to $123 on October 17, 2025, up nearly 40% from a year ago, lifting its market value to about $150 billion. The company settled U.S. patent litigation over HIV drug Biktarvy, blocking generics until 2036. Its new HIV prevention shot Yeztugo is seeing strong uptake, and Moody’s raised Gilead’s outlook to “Positive.” Gilead also announced a $1.5 billion cell therapy deal with Pregene.
17 October 2025
··
Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

The FDA approved Ionis’s Dawnzera for hereditary angioedema and Precigen’s Papzimeos for recurrent respiratory papillomatosis, marking a first for viral immunotherapy. Gilead’s Kite Pharma will acquire Interius BioTherapeutics for $350 million. Johnson & Johnson announced a $2 billion biomanufacturing facility in North Carolina. Apollo Hospitals’ managing director sold a $170 million stake in a major block trade.
22 August 2025
·····
1 2

Stock Market Today

  • HSBC Spotlights 10 Overlooked Asian Stocks Beyond AI Momentum
    May 20, 2026, 12:07 AM EDT. HSBC highlights 10 'forgotten gem' stocks in Asia outside the dominant AI sector, which has fueled gains in Nvidia, TSMC, and Samsung Electronics. The bank warns of concentration risks in the FTSE Asia ex-Japan index, where over half the returns came from just three AI-related firms. HSBC's list features undervalued companies with strong returns, market share growth and solid dividends. Names include Hong Kong Exchange, South Korea's Samyang Foods, Indonesia's PT Telkom, Fuyao Glass Industry, WuXi AppTec, and India's Godrej Properties. These firms benefit from scalable business models, resilient margins, and expanding market positions. HSBC sees potential in sectors overlooked amid AI hype, emphasizing diversification opportunities for investors seeking sustained growth in Asia.

Latest articles

Wall Street Hit by Yield Jolt With Nvidia Up Next

Wall Street Hit by Yield Jolt With Nvidia Up Next

20 May 2026
U.S. stock ETFs remained lower late Tuesday after Wall Street’s main indexes fell for a third straight session, pressured by rising Treasury yields and caution ahead of Nvidia’s earnings. The SPDR S&P 500 ETF dropped 0.7% to $733.73. The 10-year Treasury yield hit 4.687%, its highest since January 2025, before easing. Nvidia shares slipped 0.7% after hours, with traders bracing for a major move post-earnings.
Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

20 May 2026
Viavi Solutions shares dropped 7.1% in after-hours trading Tuesday after the company announced a $500 million public stock offering aimed at repaying debt. The offering, unveiled just after the Nasdaq close, could add roughly 10.1 million new shares. Viavi plans to use proceeds to pay down a $450 million loan. Total debt would fall to $650 million, according to a preliminary SEC filing.
Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

20 May 2026
Analog Devices agreed to acquire Empower Semiconductor for $1.5 billion in cash, sending ADI shares up 1.36% to $419.95 in after-hours trading after closing down 1.02%. The deal, approved by both boards, is expected to close in the second half of 2026 pending regulatory review. Empower CEO Tim Phillips will continue to lead integrated voltage regulator work after the merger.
Go toTop